N/A Completed N=25 Other

Use Feasibility of the iThermonitor in Pediatrics Patients on Myelosuppresive Therapies

leukemia · Acute Myeloid Leukemia · Non-Hodgkin's Lymphoma

Source: ClinicalTrials.gov NCT02410252 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jul 2018

Primary outcomePrimary: Percent of Participants That Successfully Used the iThermonitor — 100; 75; 63 % of participants

Summary

This is a pilot study to evaluate the use feasibility of the iThermonitor, a continuous temperature monitoring device, as a clinical support and patient self-management tool in the management of pediatrics patients on myelosuppressive therapies for acute leukemia and other childhood cancers.

Outcome Measures

Outcome	Result	p-value
PRIMARY Percent of Participants That Successfully Used the iThermonitor	100; 75; 63	—
SECONDARY Care Giver Anxiety	12; 3; 1; 3; 16; 2	0.13
SECONDARY Usability, Acceptability and Satisfaction	8; 9; 0; 2; 13; 6	0.05

Eligibility Criteria

Inclusion Criteria

Dyad consists of a pediatric patient aged 2-17 years undergoing myelosuppressive therapies for acute leukemias and other childhood cancers.
Dyad also includes a caregiver, ≥ 18 years of age that is willing to participate in the study.
Ability of caregiver or patient (if old enough) to read and speak English.
If applicable, willingness of the patient to shave axillary (armpit) hair.
Caregiver (parent or legal guardian) must give informed consent for dyad participation.

Exclusion Criteria

Patient has a history of allergy to hydrogel dressing or ongoing skin diseases
Patients with ongoing febrile illness or documented infectious disease.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02410252). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.